Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Telomir Pharmaceuticals Inc TELO

Healthcare
Telomir Pharmaceuticals, Inc. is a United States-based company. The Company operates as pre-clinical-stage pharmaceutical company focused on developing TELOMIR-1 small molecule to lengthen the deoxyribonucleic acid’s (DNA) protective telomere caps to affect age reversal. It selectively affects the processes that drive the concentration and accumulation of iron and copper in the serum that... see more

NDAQ:TELO - Post Discussion

Telomir Pharmaceuticals Inc > InvestorNewsBreaks - Telomir Pharmaceuticals (NASDAQ: TELO)
View:
Post by whytestocks on Nov 21, 2024 11:16am

InvestorNewsBreaks - Telomir Pharmaceuticals (NASDAQ: TELO)

JUST IN: $TELO InvestorNewsBreaks - Telomir Pharmaceuticals (NASDAQ: TELO) Unveils Preclinical Success of Telomir-1 in Age-Reversal ScienceTelomir Pharmaceuticals (NASDAQ: TELO) announced promising preclinical results for Telomir-1, a compound designed to reverse biological aging and enhance longevity. In collaboration with Nagi Biosciences, the study utilized advanced microfluidic technology to test Telomir-1 on aging model organi...TELO - InvestorNewsBreaks - Telomir Pharmaceuticals (NASDAQ: TELO) Unveils Preclinical Success of Telomir-1 in Age-Reversal Science
Be the first to comment on this post
Telomir Pharmaceuticals Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities